National Heart, Lung, and Blood Institute
Browse

Figures, Schemes and SI for "Isolation and Identification of a Urinary Biomarker for Lung Cancer: 27-Nor-5β-cholestane-3α,7α,12α,24<i>R</i>,25<i>S</i> pentol glucuronide and its Deuterated Analog"

Download (3.3 MB)
figure
posted on 2024-06-12, 13:01 authored by Burchelle BlackmanBurchelle Blackman, Natarajan Raju, Chandrasekhar Mushti, Kelly Lane, Daxeshkumar PatelDaxeshkumar Patel, Curtis Harris, Rolf E. Swenson
<p dir="ltr"><b>Abstract: </b>An untargeted metabolomic study identified four potential lung cancer diagnostic biomarkers in human urine. One of the potential biomarkers was an unidentified feature possessing a m/z value of 561+. “561+” was isolated from human urine and tentatively identified as 27-nor-5β-cholestane-3α,7α,12α,24,25 pentol glucuronide with unknown C24,25 stereochemistry by <sup>1</sup>H NMR and mass spectrometry. In a prior report, the C24,25 stereochemistry of the aglycone, 27-nor-5β-cholestane-3α,7α,12α,24,25 pentol, was found to be 24<i>S</i>,25<i>R </i>by GC analysis of the acetonide-TMS derivative. An authentic sample was prepared and found not to have the same stereochemistry as ”561+”. To identify the C24,25 stereochemistry, four C24,C25 diastereoisomeric alcohols of 27-nor-5β-cholestane-3α,7α,12α,24,25 pentol were prepared from chiral amino acids. Using an LCMS method, the C24,C25 stereochemistry of the “561+” aglycone was determined to be 24<i>R</i>,25<i>S</i>. With the correct aglycone in hand, it was coupled with glucuronic acid, to compete the first reported synthesis of 27-nor-5β-cholestane-3α,7α,12α,24<i>R</i>,25S pentol glucuronide. Deuterium labeled 27-nor-5β-cholestane-3α,7α,12α,24<i>R</i>,25<i>S</i> pentol was also synthesized for use as an internal standard for MS quantitation.</p><p dir="ltr"><b>Scheme 1. </b>Retrosynthetic analysis for 27-nor-5β-cholestane-3α,7α,12α,24,25 pentol glucuronides <b>1a-d.</b></p><p dir="ltr"><b>Scheme 2</b>. Synthesis of chiral alkene <b>5a.</b></p><p dir="ltr"><b>Scheme 3</b>. Synthesis of chiral aglycone <b>2a</b>.</p><p dir="ltr"><b>Scheme 4</b>. Synthesis of <b>1a</b></p><p dir="ltr"><b>Scheme 5. </b>Synthesis of <b>16</b></p><p dir="ltr"><b>Figure 1</b>. ESI+ mass spectrum of 27-nor-5β-cholestane-3α,7α,12α,24,25 pentol. Pseudomolecular ion m/z = 385.3+ used for detection and quantitation is marked with an asterisk (*). The peaks marked with an arrow are additional fragment ions derived from the parent molecular ion m/z = 439.3+ ([M+H]+).</p><p dir="ltr"><b>Figure 2</b>. Stereochemistry of 27-nor-5β-cholestane-3α,7α,12α,24,25 pentol released from human urine treated with β-glucuronidase. ESI+ mass extracted chromatograms at m/z 358.5+. (A) Untreated urine. (B) Urine treated with β-glucuronidase. (C) Mixture of the four diastereoisomeric aglycones <b>2a-d</b>.</p><p dir="ltr"><b>Figure 3</b>. Comparison of LCMS retention times between “561+” in urine vs standard 1a. (A) ESI- extracted mass chromatograms at m/z = 613.34+ (M-H). (B) ESI+ extracted mass chromatograms at m/z = 615.34 (M+H).</p><p dir="ltr"><b>Figure 4</b>. Identification of “561+”. (A) ESI- mass spectrum; (B) ESI+ mass spectrum. Peaks marked with an asterisk (*) are fragment ions derived from m/z 615.3+; (C) ESI+ MS/MS of m/z 615.34.</p><p dir="ltr"><br></p><p dir="ltr"><br></p>

Funding

Intramural Research Program of the NIH, NCI/CCR

History

Related Materials

Usage metrics

    National Heart, Lung, and Blood Institute

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC